20170523 8K Annual Meeting







UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 

FORM 8-K



CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): May 17, 2017

_______________________

CRYOLIFE, INC.

(Exact name of registrant as specified in its charter)
_________________________



Florida

1-13165

59-2417093

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)



1655 Roberts Boulevard, N.W., Kennesaw, Georgia  30144
(Address of principal executive office) (zip code)

Registrant's telephone number, including area code: (770) 419-3355

_____________________________________________________________

(Former name or former address, if changed since last report)

_________________________



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):



Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)



Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)



Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

6761510v2 


 

 

 

Section 5 Corporate Governance and Management



Item 5.07   Submission of Matters to a Vote of Security Holders.



At CryoLife, Inc.’s (the “Company” or “CryoLife”) 2017 Annual Meeting of Stockholders held on May 17, 2017 (the “Annual Meeting”), CryoLife’s stockholders elected each individual that was nominated for election as director of the Company to serve until the next annual meeting or until their successors are elected and have been qualified. The stockholders also (i) approved, by non-binding vote, the compensation paid to CryoLife’s named executive officers, as disclosed pursuant to Item 402 of Regulation S-K, including the Compensation Discussion and Analysis, compensation tables and narrative discussion, (ii) advised, by non-binding vote, on the frequency of stockholder advisory votes on the compensation of our named executive officers, (iii) approved certain amendments to the CryoLife, Inc. Equity and Cash Incentive Plan, and (iv) ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the Company for the year ending December 31, 2017. The stockholders did not approve a proposal to add three million shares to the CryoLife, Inc. Equity and Cash Incentive Plan.



The final results of the voting on each matter of business at the 2017 Annual Meeting are as follows:



Election of Directors



Name

Votes For

Votes Withheld

Broker Non-Votes

Thomas F. Ackerman

24,859,707  588,094  5,287,137 

Daniel J. Bevevino

23,868,956  1,578,845  5,287,137 

James W. Bullock

25,127,480  320,321  5,287,137 

Ronald C. Elkins, M.D.

23,717,079  1,730,722  5,287,137 

J. Patrick Mackin

25,085,543  362,258  5,287,137 

Ronald D. McCall, Esq.

22,926,555  2,521,246  5,287,137 

Harvey Morgan

25,214,718  233,083  5,287,137 

Jon W. Salveson

24,137,725  1,310,076  5,287,137 

 

Approval, by non-binding vote of the compensation paid to CryoLife’s named executive officers, as disclosed pursuant to Item 402 of Regulation S-K, including the Compensation Discussion and Analysis, compensation tables and narrative discussion.



Votes For

Votes Against

Votes Abstain

Broker Non-Votes

20,436,621

4,946,762

64,417

5,287,138





Advisory vote on the frequency of stockholder advisory votes on the compensation of our named executive officers.



Votes For

1 year

Votes For

2 years

Votes For

3 years

Votes Abstain

Broker Non-Votes

19,601,940

50,036

5,697,495

98,330

5,287,137

-2-


 

 

 



In light of the voting results with respect to the interval at which to seek shareholders’ approval of the compensation of the named executive officers, the Company has determined, as was recommended with respect to this proposal by the Company’s board of directors in the proxy statement for the 2017 annual meeting, that the Company will hold future say on pay votes on an annual basis until the occurrence of the next advisory vote on the frequency of say on pay votes. The next advisory vote regarding the frequency of say on pay votes is required to occur no later than the Company’s 2023 annual meeting of shareholders.



Approval of certain amendments to the CryoLife, Inc. Equity and Cash Incentive Plan.



Votes For

Votes Against

Votes Abstain

Broker Non-Votes

20,319,325

4,961,273

167,203

5,287,137





Approval of the addition of three million shares to the CryoLife, Inc. Equity and Cash Incentive Plan.



Votes For

Votes Against

Votes Abstain

Broker Non-Votes

11,966,864

13,399,633

81,303

5,287,138







Ratification of the selection of Ernst & Young LLP as the independent registered public accounting firm for the Company for the year ending December 31, 2017.



Votes For

Votes Against

Votes Abstain

30,463,419

75,162

196,356

-3-


 

 

 

SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, CryoLife, Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.







 



CRYOLIFE, INC.



 



 

Date: May 23, 2017

By:       /s/D. Ashley Lee



Name:  D. Ashley Lee



Title:    Executive Vice President, Chief



            Operating Officer and Chief



            Financial Officer



 































































-4-